Filtered By:
Drug: Warfarin
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 961 results found since Jan 2013.
Direct Oral Anticoagulants Versus Vitamin K Antagonist (Warfarin) For Stroke Prevention In Frail Patients With Atrial Fibrillation: A Meta-Analysis
Proc (Bayl Univ Med Cent). 2022 Dec 22;36(2):274-275. doi: 10.1080/08998280.2022.2155926. eCollection 2023.NO ABSTRACTPMID:36876251 | PMC:PMC9980567 | DOI:10.1080/08998280.2022.2155926
Source: Baylor University Medical Center Proceedings - March 6, 2023 Category: Universities & Medical Training Authors: Rupak Desai Aobo Li Avilash Mondal Priya Shenwai Bhavyasri Merugu Frailyn J Nunez Guzman Akhil Jain Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Expert Review of Clinical Pharmacology - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research
Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis
J Cardiovasc Dev Dis. 2023 Feb 3;10(2):65. doi: 10.3390/jcdd10020065.ABSTRACTThe best method of anticoagulation for patients with peripheral artery disease (PAD) is still a topic of interest for physicians. We conducted a meta-analysis to compare the effects of direct oral anticoagulants (DOACs) with those of vitamin-K-antagonist (VKA) anticoagulants in patients with peripheral artery disease. Five databases (Medline (via PubMed), EMBASE, Scopus, Web of Science, and CENTRAL) were searched systematically for studies comparing the effects of the two types of anticoagulants in patients with PAD, with an emphasis on lower-limb...
Source: Atherosclerosis - February 24, 2023 Category: Cardiology Authors: Enik ő Pomozi Rita Nagy P éter Fehérvári P éter Hegyi Boldizs ár Kiss Fanni Dembrovszky Annam ária Kosztin S ándor Nardai Endre Zima Zolt án Szeberin Source Type: research
A Review of FXIa Inhibition as a Novel Target for Anticoagulation
Hamostaseologie. 2023 Feb;43(1):28-36. doi: 10.1055/a-1984-7021. Epub 2023 Feb 20.ABSTRACTLimitations of vitamin K antagonists as chronic oral anticoagulant therapy have largely been supplanted by direct factor IIa and factor Xa inhibitor oral anticoagulants with similar efficacy but an overall better safety profile, lack of routine monitoring, and very limited drug-drug interactions compared with agents such as warfarin. However, an increased risk of bleeding remains even with these new-generation oral anticoagulants in fragile patient populations, in patients requiring dual or triple antithrombotic therapy, or high bleed...
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Ioannis Koulas Alex C Spyropoulos Source Type: research
